Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07128550 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status changed: Recruiting → Active, Not Recruiting
    • Site details revised at 38 of 38 sites
    v9
  2. Study sites: 36 to 38v8
  3. Study sites: 34 to 36v7
  4. Study sites: 29 to 34v6
  5. Study sites: 26 to 29v5
Show 3 earlier versionsHide 3 earlier versions
  1. Study sites: 20 to 26v4
  2. Study sites: 16 to 20v3
  3. Study sites: 12 to 16
    • Eligibility criteria revised
    • Secondary endpoints revised (3)
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a multicenter, open label, randomized Phase 3 clinical study to evaluate tobevibart + elebsiran in participants with Chronic HDV Infection not virologically suppressed with bulevirtide
Trial Details
NCT Number NCT07128550
Lead Sponsor Vir Biotechnology, Inc.
Conditions
(from sponsor)		 Viral Hepatitis
Related terms Digestive System Diseases, Hepatitis, Hepatitis D, Hepatitis D, Chronic, Liver Diseases
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov